Global circulating tumor cells market is expected to reach USD 2.28 billion by 2020. Growing prevalence of cancer has heightened the need for effective and early diagnosis. Circulating tumor cells cater to this heightened need and are therefore, expected to witness a surge in demand during the forecast period. Majority of cancer deaths are due to circulating tumor cells and an early diagnosis of the same is expected to increase survival rates. Targeted therapy in cancer has large untapped opportunities and therefore, entails extensive R&D investments aimed at new product development. However, high procedure costs and lack of commercialized products are expected to impede market growth during the forecast period.
Browse the report:http://www.orbisresearch.com/reports/index/circulating-tumor-cells-market-analysis-by-technology-filtration-centrifugation-immunological-and-immunomagnetic-optical-molecular-tumor-cell-enrichment-and-detection-by-application-prostate-cancer-breast-cancer-colorectal-cancer-and-segment-forecasts-to-
Further key findings from the study suggest:
Tumor cell detection was the leading product segment in 2013 primarily owing to the advantages associated with therapeutic monitoring and high procedure prices. Its market is expected to reach an estimated value of over USD 250.0 million by 2020.
Molecular technique emerged as the largest tumor cell detection segment in 2013. This technique holds several advantages over optical tumor cell detection technique and therefore, witnesses higher usage rates. Notable advantages of molecular tumor cell detection techniques include higher sensitivity and high-throughput analysis. Moreover, the introduction of new products such as CellSearch by Janssen Pharmaceutical is expected to drive segment growth.
Request a sample of the report:http://www.orbisresearch.com/contacts/request-sample/60629
Tumor cell enrichment is also expected to witness lucrative growth over the next six years. The market is primarily driven by rapidly growing demand for prognostic technologies coupled with the presence of high patient unmet needs.
Immunological and immunomagnetic techniques associated with tumor cell enrichment were the largest market in 2013, accounting for a share of over 50.0%. It is the most commonly used diagnostic technique and therefore, hold high market penetration rates.
Buy the report@http://www.orbisresearch.com/contact/purchase/60629
North America was the most revenue generating market in 2013. Presence of sophisticated healthcare infrastructure, growing prevalence of cancer and relatively larger presence of commercialized products are some factors attributing to its market position.
The Asia Pacific circulating tumor cells market holds lucrative future growth opportunities. High prevalence of unmet patient needs, constantly improving healthcare infrastructure and increasing healthcare expenditure levels in the emerging markets of India and China are some factors accounting for its market attractiveness.
Some key players of the circulating tumor cells market include AVIVA BioSciences Corporation, Silicon Biosystems S.p.A, Advanced Cell Diagnostics Inc, Celula Inc., Epic Sciences Inc., AdnaGen AG, Vitatex Inc, Rarecells Inc. and Fluxion Biosciences Inc.
Major points From table Of Contents:
Chapter One: Executive Summary
Chapter Two: Circulating Tumor Cells Industry Outlook
Chapter Three: Circulating Tumor Cells Technology Outlook
Chapter Four: Circulating Tumor Cells Application Outlook
Chapter Five: Circulating Tumor Cells Regional Outlook
Chapter Six: Competitive Landscape
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019